Thomas Hubbard

Oral cavity and oropharyngeal squamous cell carcinoma—an update

The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation

Potential of Substance P Antagonists as Antiemetics

Chemotherapy-Induced Nausea and Vomiting

Principles and Practice of Reconstructive Surgery for Head and Neck Cancer

Fluorine in medicinal chemistry

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Trifluoroacetic acid: Uses and recent applications in organic synthesis

Axially Chiral 1,7-Naphthyridine-6-carboxamide Derivatives as Orally Active Tachykinin NK₁ Receptor Antagonists:  Synthesis, Antagonistic Activity, and Effects on Bladder Functions

Recent applications of the Suzuki–Miyaura cross-coupling reaction in organic synthesis

An Efficient and Cost-Effective Synthesis of 2-Phenyl-3-aminopyridine

The Many Roles for Fluorine in Medicinal Chemistry

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Palladium-Catalyzed Suzuki−Miyaura Cross-Coupling Reactions Employing Dialkylbiaryl Phosphine Ligands

Selected Patented Cross-Coupling Reaction Technologies

Electrophilic Trifluoromethylation by Use of Hypervalent Iodine Reagents

Synthesis of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP)

The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures

Large-Scale Applications of Transition Metal-Catalyzed Couplings for the Synthesis of Pharmaceuticals

Assessing Atropisomer Axial Chirality in Drug Discovery and Development

Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension

Hypoxia-Inducible Factor 1α Is a Critical Downstream Mediator for Hypoxia-Induced Mitogenic Factor (FIZZ1/RELMα)–Induced Pulmonary Hypertension

Discovery and Biological Characterization of (2R,4S)-1′-Acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4′-bipiperidine-1-carboxamide as a New Potent and Selective Neurokinin 1 (NK₁) Receptor Antagonist Clinical Candidate

Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Leave the Fat, Skip the Bolster: Thinking outside the Box in Lower Third Nasal Reconstruction

Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound

Spiro-piperidine non-peptide neurokinin-1 receptor antagonists

Sustained Cardiovascular Actions of APJ Agonism During Renin–Angiotensin System Activation and in Patients With Heart Failure